Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02049138 · ClinicalTrials.gov registry record · Phase 2
An Open-label Extension Study Evaluating the Safety and Efficacy of Upadacitinib (ABT-494) in Adults With Rheumatoid Arthritis
A Phase 2 study, sponsored by AbbVie.
- Completed
- Registry status
- Phase 2
- Development phase
- 493
- Enrollment target
NCT02049138 is a Phase 2 study that has completed, run by AbbVie. The registered enrollment target is 493 participants.
The verdict
NCT02049138, a Phase 2 study, has completed, sponsored by AbbVie.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 493 participants
- Enrollment target
Study Summary
The primary objective of the study is to evaluate the long-term safety, tolerability, and efficacy of upadacitinib in adults with rheumatoid arthritis (RA) who have completed a preceding randomized controlled trial with upadacitinib.
Interventions
- DRUG Upadacitinib
- BIOLOGICAL Pneumococcal 13-valent conjugate vaccine (PCV-13)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 493 participants |
| Start Date | 2014-01-24 |
| Est. Completion | 2021-07-29 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02049138
The ClinicalTrials.gov registry entry for NCT02049138 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 493 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AbbVie, which has 526 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Upadacitinib is the first listed.
NCT02049138 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02049138 about?
NCT02049138 is a clinical study titled "An Open-label Extension Study Evaluating the Safety and Efficacy of Upadacitinib (ABT-494) in Adults With Rheumatoid Arthritis". The primary objective of the study is to evaluate the long-term safety, tolerability, and efficacy of upadacitinib in adults with rheumatoid arthritis (RA) who have completed a preceding randomized controlled trial with upadacitinib.
What is the current status of trial NCT02049138?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 493 participants. The study started on 2014-01-24. Estimated completion is 2021-07-29.
What interventions are being tested in trial NCT02049138?
The interventions under investigation include: Upadacitinib (DRUG), Pneumococcal 13-valent conjugate vaccine (PCV-13) (BIOLOGICAL).
Who is sponsoring clinical trial NCT02049138?
This trial is sponsored by AbbVie, which has 526 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.